CN116942742B - 一种降尿酸中药组合物及其制备方法 - Google Patents
一种降尿酸中药组合物及其制备方法 Download PDFInfo
- Publication number
- CN116942742B CN116942742B CN202311211158.9A CN202311211158A CN116942742B CN 116942742 B CN116942742 B CN 116942742B CN 202311211158 A CN202311211158 A CN 202311211158A CN 116942742 B CN116942742 B CN 116942742B
- Authority
- CN
- China
- Prior art keywords
- tea
- parts
- mixing
- pile fermentation
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 49
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 47
- 229940116269 uric acid Drugs 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 title claims abstract description 27
- 239000000203 mixture Substances 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000001603 reducing effect Effects 0.000 title claims abstract description 17
- 244000269722 Thea sinensis Species 0.000 claims abstract description 91
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 34
- 235000020279 black tea Nutrition 0.000 claims abstract description 34
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 30
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 30
- 241000233779 Cyclocarya paliurus Species 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000013616 tea Nutrition 0.000 claims description 57
- 238000000855 fermentation Methods 0.000 claims description 42
- 230000004151 fermentation Effects 0.000 claims description 41
- 239000000463 material Substances 0.000 claims description 27
- 238000002156 mixing Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 23
- 238000005303 weighing Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 14
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 230000001965 increasing effect Effects 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 238000002386 leaching Methods 0.000 claims description 7
- 229920000858 Cyclodextrin Polymers 0.000 claims description 6
- 239000001116 FEMA 4028 Substances 0.000 claims description 6
- 241000288049 Perdix perdix Species 0.000 claims description 6
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 6
- 229960004853 betadex Drugs 0.000 claims description 6
- 238000001704 evaporation Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000008213 purified water Substances 0.000 claims description 6
- 238000007789 sealing Methods 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 239000011259 mixed solution Substances 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 238000004806 packaging method and process Methods 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 238000005096 rolling process Methods 0.000 claims description 3
- 238000010025 steaming Methods 0.000 claims description 3
- 238000009461 vacuum packaging Methods 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000004659 sterilization and disinfection Methods 0.000 claims description 2
- 239000011362 coarse particle Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 42
- 239000008280 blood Substances 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 28
- 241000700159 Rattus Species 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 210000003734 kidney Anatomy 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000002023 wood Substances 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 201000001431 Hyperuricemia Diseases 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 6
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 4
- 230000029142 excretion Effects 0.000 description 4
- 150000002212 flavone derivatives Chemical class 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 150000008442 polyphenolic compounds Chemical class 0.000 description 4
- 235000013824 polyphenols Nutrition 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000014347 soups Nutrition 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 241001425752 Parthenos Species 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 229960003459 allopurinol Drugs 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- -1 flavone glycoside Chemical class 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000003345 hyperglycaemic effect Effects 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003212 purines Chemical class 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- CXQWRCVTCMQVQX-LSDHHAIUSA-N (+)-taxifolin Chemical compound C1([C@@H]2[C@H](C(C3=C(O)C=C(O)C=C3O2)=O)O)=CC=C(O)C(O)=C1 CXQWRCVTCMQVQX-LSDHHAIUSA-N 0.000 description 1
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- SBMBZNDXQINZKP-UHFFFAOYSA-N 2-ethoxy-5-hydroxynaphthalene-1,4-dione Chemical compound C1=CC=C2C(=O)C(OCC)=CC(=O)C2=C1O SBMBZNDXQINZKP-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- OBIOZWXPDBWYHB-UHFFFAOYSA-N Nobiletin Natural products C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 OBIOZWXPDBWYHB-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000061121 Rauvolfia serpentina Species 0.000 description 1
- 206010062237 Renal impairment Diseases 0.000 description 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- XCGZWJIXHMSSQC-UHFFFAOYSA-N dihydroquercetin Natural products OC1=CC2OC(=C(O)C(=O)C2C(O)=C1)c1ccc(O)c(O)c1 XCGZWJIXHMSSQC-UHFFFAOYSA-N 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229910052732 germanium Inorganic materials 0.000 description 1
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 1
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 1
- 235000010209 hesperetin Nutrition 0.000 description 1
- 229960001587 hesperetin Drugs 0.000 description 1
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000005977 kidney dysfunction Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- MRIAQLRQZPPODS-UHFFFAOYSA-N nobiletin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 MRIAQLRQZPPODS-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000004634 pharmacological analysis method Methods 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 208000022530 polyphagia Diseases 0.000 description 1
- QARYADFHOUHDSW-UHFFFAOYSA-M potassium 2H-oxazine-3-carboxylate Chemical compound O1NC(=CC=C1)C(=O)[O-].[K+] QARYADFHOUHDSW-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及一种降尿酸中药组合物及其制备方法,中药组合物是由如下原料制成:安化黑茶芽尖5‑10重量份、平卧菊三七3‑5重量份、青钱柳3‑5重量份、分心木4‑5重量份和橘皮2‑3重量份。本发明提供了一种可以降低体内尿酸并且服用者耐受性和安全性较好、副作用较小的中药组合物。本发明提供的中药组合物具有很好的降尿酸和降血糖的作用。
Description
技术领域
本发明涉及中药保健养生技术领域,具体的说,涉及一种降尿酸中药组合物及其制备方法。
背景技术
高尿酸血症和高血糖症是常见的代谢紊乱性疾病。尿酸是人体中嘌呤化合物的最终代谢产物,高尿酸血症是由人体尿酸囤积过多,而身体***量过少导致的。由于人体缺乏能够分解嘌呤化合物的酶,只能靠肾脏代谢将多余的尿酸排出体外,一旦肾脏代谢功能紊乱或摄入含大量嘌呤的食物,使人体中尿酸浓度过高,两次非同日的血尿酸浓度大于420umol/L便会诊断为高尿酸血症。尿酸浓度过高时,会结晶成尿酸盐,沉积在关节滑膜、滑囊、软骨及其他组织中,从而引起痛风。现代医学根据成因将高尿酸血症分为生成增多型和***减少型,并依据肾功能情况选用抑制尿酸生成药如别嘌醇,或促进尿酸***药如苯溴马隆、丙磺舒、苯磺唑酮等。尽管这些药物有明显的降尿酸作用,但副作用也较大,如皮疹、发热、肝肾功能障碍、造血功能异常、痛风发作等。
为此,本领域技术人员期待提供一种安全性较好、副作用较小、适合长期服用的,并可有效降低体内尿酸的中药组合物及其制备方法。
发明内容
(一)要解决的技术问题
鉴于现有技术的上述缺点、不足,本发明提供一种可以有效降低体内尿酸且服用者耐受性和安全性较好、副作用较小的中药组合物及其制备方法。
本发明提供中药组合物具有很好的降尿酸和降血糖的作用,且服用方便、口感好,副作用较低。
(二)技术方案
第一方面,本发明涉及一种降尿酸的中药组合物,其是由如下原料制成:安化黑茶芽尖5-10重量份、平卧菊三七3-5重量份、青钱柳3-5重量份、分心木4-5重量份和橘皮2-3重量份。
优选地,所述原料组成为:安化黑茶芽尖7重量份、平卧菊三七4.5重量份、青钱柳4.5重量份、分心木4重量份和橘皮2.5重量份。其中的安化黑茶芽尖为陈放15年以上安化黑茶芽尖。
优选地,所述中药组合物为饮片、速溶药粉或口服液。
第二方面,本发明涉及一种降尿酸的中药组合物的制备方法,其是由如下原料制成:安化黑茶芽尖5-10重量份、平卧菊三七3-5重量份、青钱柳3-5重量份、分心木4-5重量份和橘皮2-3重量份;所述制备方法包括:
S1、安化黑茶的炒制及渥堆发酵:
S2、平卧菊三七、青钱柳杀青及渥堆发酵:
S3、使用S1处理的茶叶和S2处理的药材,再称取洗净的分心木和橘皮,加上洗净的分心木和橘皮,制作饮片、速溶药粉或口服液。
根据本发明较佳实施例,S1包括如下步骤:
(1)称取安化黑茶芽尖,以每100g安化黑茶芽尖加水10-40g混匀,混匀后放入炒茶机进行回软,炒茶机进锅温度为190-210℃,炒10-30min,出锅叶温控制为55-65℃;
(2)取步骤(1)中回软后的茶叶放入渥堆室,渥堆室内温度为20-35℃,湿度80-90%,渥堆高度为75-85cm,堆内温度上升至75℃时进行翻堆,渥堆时间600-650h;
(3)取步骤(2)中渥堆发酵后的茶叶放入烘干机进行干燥,通过70-75℃高温蒸发水分,时间35-40min,水分保持在8-12%。
根据本发明较佳实施例,S2包括如下步骤:
(1)分别取新鲜平卧菊三七和青钱柳,清洗,晒干,杀菌;
(2)取步骤(1)中原料粗碎,混匀,将原料粗颗粒放入杀青机中,以250-300℃高温蒸软,时间10min,水分保持在30-35%;
(3)取步骤(2)中的药材放入揉捻机中,使茶叶卷成条,时间10min;
(4)取步骤(3)中的药材放入炒茶机中干燥,炒茶机进锅温度为250-300℃,炒20-30min,出锅叶温控制为60-70℃,水分保持在15-20%;
(5)取步骤(4)中的药材放入渥堆室,渥堆室内保持温度25-28℃,湿度85-90%,渥堆高度为65-75cm,当堆内温度上升至75℃时进行翻堆,渥堆时间900-950h;
(6)取步骤(5)中渥堆发酵后的药材放入烘干机进行干燥,通过70-75℃高温蒸发水分,时间40-45min。
根据本发明较佳实施例,S3包括如下步骤:取S1处理好的茶叶和S2处理的药材,再称取洗净的分心木和橘皮,将茶叶、平卧菊三七、青钱柳、分心木、橘皮按照5-10:3-5:3-5:4-5:2-3的重量比粗碎后混合均匀,在无菌环境下定量装袋,封口,即得饮片。
根据本发明较佳实施例,S3包括如下步骤:取S1处理好的茶叶和S2处理的药材,再称取洗净的分心木和橘皮,将茶叶、平卧菊三七、青钱柳、分心木、橘皮按照5-10:3-5:3-5:4-5:2-3的重量比混合,加入10-20倍重量的纯净水,煮至80-100℃,时间30-40min,浸提三次后合并浸提液,使用80-100目的滤筛过滤,将滤液放入旋转蒸发仪中浓缩,浓缩汁的体积为浓缩前滤液的1/3-1/4,得到浓缩汁;取浓缩汁,加入CaCl2溶液和β-环糊精,CaCl2添加量为浓缩汁的2-2.5wt.%,β-环糊精添加量为浓缩汁的0.3-0.6wt.%,混合均匀得混合液;将混合液在1.0-3.5MPa压力下完成喷雾干燥,再经粉碎得到200-500μm的药粉,在无菌环境下定量装袋,封口,即得速溶药粉。
根据本发明较佳实施例,S3包括如下步骤:取S1处理好的茶叶和S2处理的药材,再称取洗净的分心木和橘皮,将茶叶、平卧菊三七、青钱柳、分心木、橘皮按照5-10:3-5:3-5:4-5:2-3的重量比混合,加入3-5倍重量的纯净水,煮至80-100℃,时间20-30min,得药汤;使用100目滤筛过滤后,加入1倍重量份红糖、0.002倍重量份薄荷粉,混匀;杀菌后降温至30±5℃,采用无菌真空灌装方法低温灌装,即得口服液。
(三)有益效果
本发明中的中药组合物由陈放15年以上安化黑茶芽尖、平卧菊三七、青钱柳、分心木、橘皮原料制备而成。其中安化黑茶芽尖是我国特有的微生物发酵茶,其味苦、甘,性凉,归心、肺、胃经,具有解腻清头目、生津除烦渴、解毒利尿的功效,大量研究证明其具有降血脂、降尿酸、降血糖和抗氧化等功效。
本发明采用陈放15年以上安化黑茶再发酵工艺,与传统黑茶相比,其香气更悠长,滋味层次感丰富,苦涩味和刺激性降低,味醇厚且回甘,药汤亮度增加。另外,陈放15年以上安化黑茶内含丰富的茶多酚、可溶性糖、茶色素、氨基酸、咖啡碱、多酚类物质等,可通过抑制肝脏XOD和ADA活性,下调肾脏尿酸重吸收蛋白mGLUT9和蛋白质mURAT的mRNA表达水平,一方面抑制尿酸的产生,另一方面促进尿酸在肾脏的***,降低体内尿酸水平;从影响糖代谢相关酶的活性,保护胰岛细胞的活性,抑制糖代谢相关转运载体活性,清除体内自由基保护β胰岛细胞,调节肠道菌群等方面,调节体内血糖水平。黑茶陈放较久,经过长时间的后氧化作用,茶性变得较温和无刺激,能促进血液的新陈代谢、助消化、养肠胃,降三高、降血糖、还有药用功效,而且存放的时间越久,氧化程度越高,茶汤滋味越醇和。
平卧菊三七味辛、微苦,性凉,有消炎散热、活血化瘀、消肿止痛、护肝解毒等功效,内含黄酮类、茶多糖、酚类、含氮化合物、萜类、脂肪酸类、甾体类等化学活性成分,发酵处理后的平卧菊三七发酵茶内含物质发生一系列生化反应变化,极大提升了平卧菊三七茶质量,增加了其黄酮、茶多酚和茶多糖等活性成分的含量,通过它的抗氧化性,抑制脂类合成和吸收,调节脑中神经传达物质的浓度来发挥降尿酸、降血糖、降血压作用,缓解亚健康状态。
青钱柳是中国特有的单种属植物,通过发酵而来的青钱柳内含丰富的茶多糖、氨基酸、黄酮等有机影响物质,还富含人体必需的锌、硒、锗等微量元素,通过靶向选择胰腺部位,提高外周组织细胞膜上胰岛素受体敏感性与功能,使血糖、血尿酸平稳下降的同时产生一定的肾脏保护作用。特别是通过本发明发酵工艺得到的青钱柳茶,硒含量要更高,且能有效清除体内自由基,对人体有更大的保健效果。
分心木是指核桃果实中的木质中隔,表面呈淡棕色、棕褐色或棕黑色,稍有光泽,有一种苦涩味,在《本草再新》中写道:分心木入脾、肾二经,具有健脾补肾的功效。现代医学研究表明,分心木中富含丰富的儿茶素和黄酮甙,特别是对内脏脂肪,具有增加微血管弹性、降低血脂以及溶解脂肪的作用,能有效控制肥胖,还能清除自由基、延缓老化、抑制血压及血糖、降低胆固醇,同时还有抗辐射及紫外线的特殊功效。所含的二氢槲皮素和2-乙氧基胡桃醌能通过抑制肿瘤细胞的DNA合成、损伤肿瘤细胞线粒体、破坏线粒体内含物来达到抑制肿瘤的效果;含有的柚皮素是一种能调节机体T淋巴细胞水平,提高机体免疫功能和抑制肿瘤生长作用的天然化合物,柚皮素对于修复由于肿瘤或者放疗、化疗引起的继发性免疫缺陷以及杀伤癌细胞有很好的作用;β-谷甾醇和柚皮素都具有明显的增强超氧化歧化酶(SOD)活性、清除自由基、抗氧化、降低血清胆固醇的功效;分心木中还含有催吐萝芙木醇,这是一种具有明显降压作用的化合物,它能通过扩张血管改善心肌、肾、肝等器官的供血,达到调节血压的效果。
橘皮是我国常用的中药,多项研究证明,橘皮具有多种药理活性,目前已被用作改善肥胖、高脂血症和高血糖症辅助治疗药物。通过药理分析发现,其中富含丰富的黄酮类化合物,包括川陈皮素、橘皮素、甜橙黄酮等,这些化合物具有抗炎、抗氧化、抗过敏、抗肥胖、抗糖、保护心血管和抗癌等特性,对抑制黄嘌呤氧化酶和黄嘌呤脱氢酶的活性也有明显的作用,可以达到降尿酸的治疗目的。
具体实施方式
为了便于理解本发明,下文将结合较佳的实施例对本发明作更全面、细致地描述,但本发明的保护范围并不限于以下具体的实施例。除非另有定义,下文中所使用的所有专业术语与本领域技术人员通常理解的含义相同。本文中所使用的专业术语只是为了描述具体实施例的目的,并不是旨在限制本发明的保护范围。
除有特别说明,本发明中用到的各种试剂、原料均为可以从市场上购买的商品或者可以通过公知的方法制得的产品。
实施例1
本实施例制备降尿酸的中药组合物饮片,其需要准备陈放15年以上的安化黑茶芽尖,同时称量平卧菊三七、青钱柳、分心木和橘皮。中药组合物饮片的制备方法如下:
第一步:炒制和再渥堆发酵安化黑茶:
(1)称取安化黑茶牙尖,以每100g安化黑茶牙尖加水30g混匀,混匀后放入炒茶机进行回软,其炒茶机进锅温度为200℃,炒20min,出锅叶温控制为60℃。
(2)取步骤(1)中回软后的茶叶放入渥堆室,其渥堆室内温度为30℃,湿度85%,渥堆高度为80cm,堆内温度上升至75℃时进行翻堆,渥堆时间600小时。
(3)取步骤(2)中渥堆发酵后的茶叶放入烘干机进行干燥,通过75℃高温蒸发水分,时间35min,水分保持在10%。
第二步:对新鲜平卧菊三七、青钱柳和渥堆发酵:
(1)称取新鲜平卧菊三七、青钱柳,并对原料进行清洗,将清洗后的原料进行晒干,杀菌。
(2)取步骤(1)中原料粗碎,混匀,将原料粗颗粒放入杀青机中,以300℃高温蒸软,时间10min,水分保持在30%。
(3)取步骤(2)中的药材放入揉捻机中,使茶叶卷成条,时间10min。
(4)取步骤(3)中的药材放入炒茶机中干燥,其炒茶机进锅温度为300℃,炒25min,出锅叶温控制为65℃,水分保持在18%。
(5)取步骤(4)中的药材放入渥堆室,其渥堆室内保持温度25℃,湿度90%,渥堆高度为70cm,当堆内温度上升至75℃时进行翻堆,渥堆时间900小时。
(6)取步骤(5)中渥堆发酵后的药材放入烘干机进行干燥,通过75℃高温蒸发水分,时间40min。
第三步:制作中药组合物饮片,制作方法如下:
取第一步处理得到的干茶叶,和第二步得到的药材,称取7重量份的安化黑茶芽尖、4.5重量份的平卧菊三七、4.5重量份的青钱柳,再称取洗净的4重量份的分心木和2.5重量份的橘皮,分别粗碎后混合均匀,在无菌环境下定量装袋,封口,即得饮片。
实施例2
本实施例制备降尿酸的中药组合物速溶药粉,其需要准备陈放15年以上的安化黑茶芽尖,并称量平卧菊三七、青钱柳、分心木和橘皮。速溶药粉的制备方法第一步和第二步参见实施例1,仅在第三步有区别。
第三步:制作速溶药粉,制作方法如下:
取第一步处理得到的干茶叶与第二步得到的药材,称取7重量份的安化黑茶芽尖、4.5重量份的平卧菊三七和4.5重量份的青钱柳,再称取洗净的4重量份的分心木和2.5重量份的橘皮,加入12倍质量的纯净水,煮至100℃,时间40min,浸提三次后合并浸提液。浸提液使用100目的滤筛过滤,将滤液放入旋转蒸发仪中浓缩,浓缩汁的体积为浓缩前滤液的1/3;取浓缩后的浓缩汁,加入CaCl2溶液和β-环糊精,CaCl2添加量为浓缩汁的2.5wt.%,β-环糊精添加量为浓缩汁的0.5wt.%,混合均匀得混合液。放入喷雾干燥机中,以2.5MPa压力完成干燥,干燥后倒入粉碎机,筛分得到粒径为200-500μm为药粉,在无菌环境下定量装袋,封口,即得速溶药粉。
实施例3
本实施例制备降尿酸的中药组合物口服液,其需要准备陈放15年以上的安化黑茶芽尖,并称量平卧菊三七、青钱柳、分心木和橘皮。速溶药粉的制备方法第一步和第二步参见实施例1,仅在第三步有区别。
第三步:制作口服液,制作方法如下:
取第一步处理得到的干茶叶与第二步得到的药材,称取7重量份的安化黑茶芽尖、4.5重量份的平卧菊三七和4.5重量份的青钱柳,再称取洗净的4重量份的分心木和2.5重量份的橘皮,加入50重量份纯净水,煮至100℃,时间30min,得药汤。药汤使用100目滤筛过滤后,加入1重量份红糖和0.002重量份薄荷粉调味,混匀。杀菌处理后降温至30℃,采用无菌真空灌装方法低温灌装,即得口服液。
对比例1
本对比例与实施例3的区别仅在于,本对比例直接使用了陈放15年以上的安化黑茶芽尖,仅放入炒茶机进行回软和烘干机干燥以水分保持在8-12%,未进行再次渥堆发酵。其余条件和步骤参见实施例3,并制得口服液。
对比例2
本对比例与实施例3的区别仅在于,本对比例使用了只经过杀青和炒茶机处理的平卧菊三七和青钱柳,但未对平卧菊三七和青钱柳进行渥堆发酵。其余条件和步骤参见实施例3,并制得口服液。
对比例3
本对比例与实施例3的区别仅在于,本对比例的口服液原料中不含分心木和橘皮。其余条件和步骤参见实施例3,并制得口服液。
中药组合物的功效验证:
为验证本发明中药组合物降低尿酸、血糖的功效,通过建立大鼠高尿酸,高血糖模型,以模型大鼠为研究对象,研究实施例3的口服液在大鼠高尿酸,高血糖过程中的预防和减轻作用。试验包括如下内容:
(1)高血糖大鼠造模:将2.10g柠檬酸中加入100mL双蒸水配成0.1mmol/L柠檬酸溶液,在2.94g柠檬酸钠中加入100mL双蒸水配成0.1mmol/L柠檬酸钠溶液,两溶液按1∶1的比例混合,配成柠檬酸缓冲液(pH 4.5),再将链脲佐菌素(STZ)溶解其中,配成1%STZ溶液。
购买体重为(200±20)g的SD雄性大鼠,66只正常SD大鼠适应性喂养1周,选取50只健康大鼠,随机分为模型组、治疗组(实施例3口服液),每组25只,随机在其腹腔注射溶解有新鲜配制的STZ溶液,注射剂量为60mg/kg,72h后测定空腹血糖浓度,大鼠空腹血糖浓度≥16.7mmol/L时,且表现为多饮、多食、多尿等症状,表明高血糖大鼠造模成功。
于试验开始前分别测定空腹血糖浓度,治疗组的大鼠均于每天上午9:00分别灌胃600mg/kg口服液(推荐成年人每日平均用量6g,按照成年人男女平均体重为60kg计,则每日用剂量为100mg/kg。由单位体积换算可得大鼠等剂量大约是人的6倍,则大鼠每日用剂量为600mg/kg),模型组给予等体积的蒸馏水,连续30d,分别在第10、20和30天禁食12 h后剪尾,取血测定空腹血糖浓度。
(2)高尿酸模型组:购雄性SPF级SD大鼠84只,6-8周龄,体质量180-220g/只。大鼠适应性饲养1周后根据随机分组原则分为对照组(对照组每天采用蒸馏水灌胃)、模型组、别嘌醇组、对比组1(对比例1口服液)、对比组2(对比例2口服液)、对比组3(对比例3口服液)、治疗组(实施例3口服液),每组各12只。除对照组外,其余各组均分别给予腺嘌呤25mg/kg、氧嗪酸钾300mg/kg进行造模,每天1次,连续灌胃3周。血尿酸升高提示造模成功。
从诱导模型时开始给药治疗,别嘌醇组按别嘌醇20mg/kg剂量灌胃;治疗组、对比组1至对比组3均组按600mg/kg剂量予口服液进行灌胃;对照组则给予治疗组相同剂量蒸馏水灌胃;每天1次,连续3周。观察指标:给药前后血清血尿酸(UA),大鼠眼眶后静脉丛采血约1.5 ml,25°C室温自然凝血1h,2500r/min离心5 min,分离血清测定UA。
(3)实验结果如下:
表1 各组大鼠血糖浓度的比较()
。
注:*表示与模型组比较差异显著(P<0.05) ,。
从表1可以看出,治疗组大鼠在连续灌胃600mg/kg口服液30d后的血糖浓度有所下降,血糖浓度在10d后相对稳定。10d、20d、30d治疗组的血糖浓度与模型组的差异显著(P<0.05),表明长期灌胃口服液的大鼠血糖浓度低于模型组。
表2各组大鼠血尿酸浓度的比较()
。
注:*表示与模型组比较差异显著(P<0.05),。
从表2可以看出,给药前各组血尿酸比较,差异无统计学意义(P>0.05)。给药后,模型组较对照组血尿酸水平升高,提示造模成功。与模型组比较,别嘌醇组、对比组1至对比组3和治疗组血尿酸明显降低,差异有统计学意义。别嘌醇组相较于给药前对大鼠血尿酸浓度有所下降,治疗组虽然不能将血尿酸浓度相较于给药前降低,但是相比模型组升高了接近56%来说,治疗组给药前后血尿酸浓度仅升高了10.6%左右;对比组1至对比组3给药前后血尿酸浓度升高了22.7%、25.4%、22.2%。这说明,在相同的喂养和干扰条件下,与对比组1-3相比,本发明的口服液可有效抑制血尿酸的升高速度。
以上试验虽然仅以实施例3的口服液为例进行说明,但实施例1饮片和实施例2速溶药粉也同样具有相似的功效。
临床案例
赵某:男,55岁,2020年3月,因身体不适在江西中医药大学附属医院进行治疗,检查发现其空腹血糖,餐后血糖,血清血尿酸偏高,给予本发明的口服液,每次6g,口服,每天两次,早晚各服用一次,连续服用1个月后复查,发现空腹血糖,餐后血糖,血清血尿酸有所降低,继续服用2个月后,空腹血糖,餐后血糖,血清血尿酸降低至正常水平。
吴某:女,50岁,2020年6月,因单位体检发现空腹血糖,餐后血糖,血清血尿酸较正常水平偏高,给予本发明饮片,每次6g,温开水送服,每天两次,早晚各服用一次,连续服用1个月后复查,发现空腹血糖,餐后血糖,血清血尿酸有所降低,继续服用2个月后,空腹血糖,餐后血糖,血清血尿酸降低至正常水平。
刘某:男,53岁,2021年6月,因单位体检发现空腹血糖,餐后血糖,血清血尿酸偏高,给予本发明的速溶药粉,每次6g,口服,每天两次,早晚各服用一次,连续服用1个月后复查,发现空腹血糖,餐后血糖,血清血尿酸有所降低,继续服用2个月后,空腹血糖,餐后血糖,血清血尿酸降低至正常水平。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围。
Claims (4)
1.一种降尿酸中药组合物的制备方法,其特征在于,由如下原料制成:安化黑茶芽尖5-10重量份、平卧菊三七3-5重量份、青钱柳3-5重量份、分心木4-5重量份和橘皮2-3重量份;所述制备方法包括如下步骤:
S1.茶叶处理:安化黑茶的炒制及渥堆发酵;
S101.称取安化黑茶芽尖,以每100g安化黑茶芽尖加水10-40g混匀,混匀后放入炒茶机进行回软,炒茶机进锅温度为190-210℃,炒10-30min,出锅叶温控制为55-65℃;所述安化黑茶芽尖为陈放15年以上安化黑茶芽尖;
S102.取步骤S101中回软后的茶叶放入渥堆室,渥堆室内温度为20-35℃,湿度80-90%,渥堆高度为75-85cm,堆内温度上升至75℃时进行翻堆,渥堆时间600-650h;
S103.取步骤S102中渥堆发酵后的茶叶放入烘干机进行干燥,通过70-75℃高温蒸发水分,时间35-40min,水分保持在8-12%;
S2.药材处理:平卧菊三七、青钱柳杀青及渥堆发酵;
S201.分别取新鲜平卧菊三七和青钱柳,清洗,晒干,杀菌;
S202.取步骤S201中原料粗碎,混匀,将原料粗颗粒放入杀青机中,以250-300℃高温蒸软,时间10min,水分保持在30-35%;
S203.取步骤S202中的药材放入揉捻机中,使其卷成条,时间10min;
S204.取步骤S203中的药材放入炒茶机中干燥,炒茶机进锅温度为250-300℃,炒20-30min,出锅叶温控制为60-70℃,水分保持在15-20%;
S205.取步骤S204中的药材放入渥堆室,渥堆室内保持温度25-28℃,湿度85-90%,渥堆高度为65-75cm,当堆内温度上升至75℃时进行翻堆,渥堆时间900-950h;
S206.取步骤S205中渥堆发酵后的药材放入烘干机进行干燥,通过70-75℃高温蒸发水分,时间40-45min;
S3.使用经步骤S1处理的茶叶和经步骤S2处理的药材,再称取洗净的分心木和橘皮,制作饮片、速溶药粉或口服液。
2.根据权利要求1所述的制备方法,其特征在于,步骤S3包括如下步骤:取步骤S1处理好的茶叶和步骤S2处理的药材,再称取洗净的分心木和橘皮,将茶叶、平卧菊三七、青钱柳、分心木、橘皮按照5-10:3-5:3-5:4-5:2-3的重量比粗碎后混合均匀,在无菌环境下定量装袋,封口,即得饮片。
3.根据权利要求1所述的制备方法,其特征在于,步骤S3包括如下步骤:取S1处理好的茶叶和S2处理的药材,再称取洗净的分心木和橘皮,将茶叶、平卧菊三七、青钱柳、分心木、橘皮按照5-10:3-5:3-5:4-5:2-3的重量比混合,加入10-20倍重量的纯净水,煮至80-100℃,时间30-40min,浸提三次后合并浸提液,使用80-100目的滤筛过滤,将滤液放入旋转蒸发仪中浓缩,浓缩汁的体积为浓缩前滤液的1/3-1/4,得到浓缩汁;取浓缩汁,加入CaCl2溶液和β-环糊精,CaCl2添加量为浓缩汁的2-2.5wt.%,β-环糊精添加量为浓缩汁的0.3-0.6wt.%,混合均匀得混合液;将混合液在1.0-3.5MPa压力下完成喷雾干燥,再经粉碎得到200-500μm的药粉,在无菌环境下定量装袋,封口,即得速溶药粉。
4.根据权利要求1所述的制备方法,其特征在于,步骤S3包括如下步骤:取S1处理好的茶叶和S2处理的药材,再称取洗净的分心木和橘皮,将茶叶、平卧菊三七、青钱柳、分心木、橘皮按照5-10:3-5:3-5:4-5:2-3的重量比混合,加入3-5倍重量的纯净水,煮至80-100℃,时间20-30min,得药汤;使用100目滤筛过滤后,加入1倍重量份红糖、0.002倍重量份薄荷粉,混匀;杀菌后降温至30±5℃,采用无菌真空灌装方法低温灌装,即得口服液。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311211158.9A CN116942742B (zh) | 2023-09-20 | 2023-09-20 | 一种降尿酸中药组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311211158.9A CN116942742B (zh) | 2023-09-20 | 2023-09-20 | 一种降尿酸中药组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116942742A CN116942742A (zh) | 2023-10-27 |
CN116942742B true CN116942742B (zh) | 2023-12-19 |
Family
ID=88447722
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311211158.9A Active CN116942742B (zh) | 2023-09-20 | 2023-09-20 | 一种降尿酸中药组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116942742B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103262919A (zh) * | 2013-06-17 | 2013-08-28 | 湖南省茶叶研究所 | 一种提高天尖黑毛茶品质的加工方法 |
CN103493916A (zh) * | 2013-09-26 | 2014-01-08 | 谢大高 | 二次发酵的黑茶及其生产方法和设备 |
CN105379886A (zh) * | 2015-11-11 | 2016-03-09 | 贺志弘 | 一种防治高尿酸血症的黑茶组合物及其制备方法 |
CN105832794A (zh) * | 2016-06-06 | 2016-08-10 | 江西本草天工科技有限责任公司 | 平卧菊三七在制备防治高尿酸血症药物、保健食品或功能食品中的应用 |
CN108402224A (zh) * | 2018-05-15 | 2018-08-17 | 肖胜君 | 一种青钱柳黑茶及其制备方法 |
CN109480006A (zh) * | 2018-12-07 | 2019-03-19 | 成都四海生物科技有限公司 | 平卧菊三七发酵茶的发酵制作工艺 |
CN110839730A (zh) * | 2019-11-28 | 2020-02-28 | 江西轩豪中药饮片有限公司 | 一种青钱柳饮片的堆卧发酵方法 |
-
2023
- 2023-09-20 CN CN202311211158.9A patent/CN116942742B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103262919A (zh) * | 2013-06-17 | 2013-08-28 | 湖南省茶叶研究所 | 一种提高天尖黑毛茶品质的加工方法 |
CN103493916A (zh) * | 2013-09-26 | 2014-01-08 | 谢大高 | 二次发酵的黑茶及其生产方法和设备 |
CN105379886A (zh) * | 2015-11-11 | 2016-03-09 | 贺志弘 | 一种防治高尿酸血症的黑茶组合物及其制备方法 |
CN105832794A (zh) * | 2016-06-06 | 2016-08-10 | 江西本草天工科技有限责任公司 | 平卧菊三七在制备防治高尿酸血症药物、保健食品或功能食品中的应用 |
CN108402224A (zh) * | 2018-05-15 | 2018-08-17 | 肖胜君 | 一种青钱柳黑茶及其制备方法 |
CN109480006A (zh) * | 2018-12-07 | 2019-03-19 | 成都四海生物科技有限公司 | 平卧菊三七发酵茶的发酵制作工艺 |
CN110839730A (zh) * | 2019-11-28 | 2020-02-28 | 江西轩豪中药饮片有限公司 | 一种青钱柳饮片的堆卧发酵方法 |
Non-Patent Citations (6)
Title |
---|
Tea and its components reduce the production of uric acid by inhibiting xanthine oxidase;Dan Wu et al.;《Food & Nutrition Research》;第66卷;第8239页 * |
二次渥堆对安化黑毛茶品质形成的影响研究;曾斌 等;《食品工业科技》;第36卷(第17期);第127-131页 * |
云南分心木提取物对小鼠高尿酸血症模型治疗作用研究;张伟 等;《天然产物研究与开发》;第33卷;摘要 * |
安化黑茶降尿酸作用及其机理;龚雨顺 等;《中国茶叶》;第45卷(第4期);摘要 * |
赵春杰.《告别痛风》.华龄出版社,2020,第124页. * |
青钱柳化学成分及抗代谢性疾病药理作用研究进展;徐若宸 等;《中草药》;第54卷(第9期);摘要 * |
Also Published As
Publication number | Publication date |
---|---|
CN116942742A (zh) | 2023-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101624570B (zh) | 中药培养养殖肉灵芝方法及养殖肉灵芝保健品的制备方法 | |
KR100404979B1 (ko) | 숙취해소용 음료 및 그 제조 방법 | |
CN107648454A (zh) | 一种补肾膏滋及其制备方法 | |
CN107751993A (zh) | 一种抗疲劳膏滋及其制备方法 | |
CN107136370A (zh) | 一种具有抗肿瘤功效的中药发酵饮料及其制备方法 | |
KR101830048B1 (ko) | 가자나무열매추출물 및 암라추출물을 포함하는 비만 또는 고지혈증 개선용 식품 조성물 | |
CN106617049A (zh) | 一种含辣木叶提取物的蜂胶类保健品及其制备方法 | |
CN1403017A (zh) | 富硒魔芋绿茶保健食品 | |
CN116942742B (zh) | 一种降尿酸中药组合物及其制备方法 | |
CN101427833B (zh) | 糜米低醇饮料的制作方法 | |
CN110693029A (zh) | 一种降血糖桑叶苦瓜功能食品 | |
KR20040101598A (ko) | 생약자원으로부터 얻은 비만 치료 및/또는 예방 활성분획조성물 | |
CN104431163A (zh) | 一种灵芝绿茶及其制备方法 | |
CN108260682A (zh) | 一种降血糖、降血脂和降血压的保健茶 | |
CN107712890A (zh) | 一种宁心安神膏滋及其制备方法 | |
CN107213261A (zh) | 有机硒组合物、其制备方法及其用途 | |
CN102308989B (zh) | 一种具有保健功能的红蚁、葡萄、蜂胶提取物的组合物 | |
KR101093006B1 (ko) | 미생물을 이용한 우황 청심원 원료 함유 건강식품의 제조방법 및 그 제조방법에 의해 제조된 건강식품 | |
CN111729056A (zh) | 抗癌的药物组合物及其制备方法 | |
CN111150065A (zh) | 沙棘水溶性提取物在抑制Tau蛋白磷酸化制剂中的应用 | |
CN110679688A (zh) | 一种蜂蜜乌龙茶饮品 | |
CN111773263A (zh) | 治疗肾癌的药物组合物及其制备方法 | |
CN108635560A (zh) | 一种治疗淋巴瘤的中药及其制备方法 | |
CN107384688A (zh) | 胡枝子红三叶养生酒的酿造方法 | |
CN111568935B (zh) | 赤苍藤提取物在制备抗肿瘤药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |